Trump DOJ Halts Cannabis Rescheduling, Industry Awaits New Timeline
Justice Department freezes cannabis rescheduling process under new administration, forcing industry to recalibrate expectations for federal reform.
The Trump administration's Justice Department has effectively paused the cannabis rescheduling process that was advancing under the previous administration, creating immediate uncertainty across the industry. The DOJ's directive halts momentum on moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, a change that would have reduced federal tax burdens and regulatory barriers for licensed operators.
The freeze arrives at a critical juncture for cannabis companies already grappling with compressed margins and limited access to traditional banking services. Multi-state operators have been particularly vocal about the 280E tax provision that prevents businesses from deducting standard operating expenses, creating effective tax rates exceeding 70% in some cases. The rescheduling delay extends this financial pressure indefinitely.
Industry executives are now recalibrating their federal reform timelines and lobbying strategies. The administration's approach signals a more conservative stance toward cannabis policy compared to the Biden era's incremental progress on banking reform and rescheduling initiatives. This shift forces companies to rely more heavily on state-level expansion opportunities rather than federal regulatory relief.
The announcement triggers broader questions about the administration's cannabis priorities, including enforcement policies and interstate commerce frameworks. Several states continue advancing their own legalization measures, creating a patchwork regulatory environment that complicates multi-state operations and capital allocation decisions.
Market participants are closely monitoring upcoming congressional hearings and DOJ statements for clearer policy direction. The regulatory uncertainty adds another variable to an already complex investment landscape, where cannabis companies trade at significant discounts to traditional consumer goods peers despite comparable growth trajectories in legal markets.